FDA Faults Impax Quality In Latest Blow To Rytary Approval
Impax Laboratories Inc. on Tuesday disclosed the U.S. Food and Drug Administration's objections to extensive quality lapses at a Taiwan manufacturing plant for its proposed Parkinson's disease medication Rytary, adding to...To view the full article, register now.
Already a subscriber? Click here to view full article